Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Mouse (Murine) PLAUR Antikörper:
anti-Human PLAUR Antikörper:
anti-Rat (Rattus) PLAUR Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal PLAUR Primary Antibody für WB - ABIN1944762
Roldan, Cubellis, Masucci, Behrendt, Lund, Danø, Appella, Blasi: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. in The EMBO journal 1990
Show all 5 Pubmed References
Mouse (Murine) Polyclonal PLAUR Primary Antibody für FACS, WB - ABIN4900558
van Zoelen, Florquin, de Beer, Pater, Verstege, Meijers, van der Poll: Urokinase plasminogen activator receptor-deficient mice demonstrate reduced hyperoxia-induced lung injury. in The American journal of pathology 2009
Show all 2 Pubmed References
Human Polyclonal PLAUR Primary Antibody für IHC (p), WB - ABIN966859
Wang, Yang, Jamaluddin, Boyd: The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. in The Journal of biological chemistry 2004
Show all 2 Pubmed References
Human Polyclonal PLAUR Primary Antibody für IP, Neut - ABIN223158
Viswanathan, Richardson, Togonu-Bickersteth, Dai, Liu, Vatsya, Sun, Yu, Munuswamy-Ramanujam, Baker, Lucas: Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B. in Journal of leukocyte biology 2009
Human Monoclonal PLAUR Primary Antibody für FACS - ABIN2472717
Gadd, Majdic, Kasinrerk, Stockinger, Maurer, Eher, Knapp: M5, a phosphoinositol-linked human myelomonocytic activation-associated antigen. in Clinical and experimental immunology 1990
Show all 3 Pubmed References
Human Monoclonal PLAUR Primary Antibody für Func, IHC (fro) - ABIN2472721
Sillaber, Baghestanian, Hofbauer, Virgolini, Bankl, Füreder, Agis, Willheim, Leimer, Scheiner, Binder, Kiener, Bevec, Fritsch, Majdic, Kress, Gadner, Lechner, Valent: Molecular and functional characterization of the urokinase receptor on human mast cells. in The Journal of biological chemistry 1997
Show all 3 Pubmed References
Human Monoclonal PLAUR Primary Antibody für FACS - ABIN2472719
Mondino, Blasi: uPA and uPAR in fibrinolysis, immunity and pathology. in Trends in immunology 2004
Show all 3 Pubmed References
The synergy of circulating factor suPAR and APOL1 (zeige APOL1 Antikörper) G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD.
Results identify soluble uPAR as a functional connection between the bone marrow and the kidney, and they implicate bone marrow immature myeloid cells as a key source of soluble uPAR that leads to glomerular dysfunction.
Plaur deficiency does not increase susceptibility to epileptogenesis after traumatic brain injury in an animal model.
Significance of the urokinase-type plasminogen activator (zeige PLAU Antikörper) and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Findings indicate a significant correlation of uPAR cleavage with breast cancer progression, but the precise biological consequence(s) of the cleavage or the cleavage products still remains to be elucidated.
interaction of full-length suPAR with alphavbeta3 integrin expressed on podocytes results in down-modulation of nephrin (zeige NPHS1 Antikörper) that may affect kidney functionality in different human pathologies characterized by increased concentration of suPAR.
In an in vivo murine angiogenesis model uPAR-deficient PTEN (zeige PTEN Antikörper) heterozygous animals increased the impaired angiogenic phenotype of uPAR knockout mice and were able to reverse the high invasive potential of PTEN (zeige PTEN Antikörper) heterozygotes.
uPAR contributes to macrophage driven atherosclerotic lesion formation.
we have firstly shown a fundamental mechanism of urokinase system(uPa (zeige PLAU Antikörper) and uPAR)-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.
our data show that uPAR is required for efficient skin tumor formation
Results provide evidence that uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA (zeige PRAP1 Antikörper) and IGF1R (zeige IGF1R Antikörper).
PLAUR to be essential for activation of Checkpoint kinase 1 (CHK1 (zeige CHEK1 Antikörper)); maintenance of cell cycle arrest after DNA damage in a TP53 (zeige TP53 Antikörper)-dependent manner; expression, nuclear import and recruitment to DNA-damage foci of RAD51 (zeige RAD51 Antikörper) recombinase (zeige RAG1 Antikörper), the principal protein involved in the homologous recombination repair pathway.
Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP (zeige CRP Antikörper)) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP (zeige CRP Antikörper)
This is the first report that PGE2 -induced uPAR expression, which stimulates invasiveness of human gastric cancer AGS (zeige JAG1 Antikörper) cells, is mediated by the EP2 receptor-dependent Src (zeige SRC Antikörper)/EGFR (zeige EGFR Antikörper)/JNK1 (zeige MAPK8 Antikörper)/2, Erk1/2 (zeige MAPK1/3 Antikörper)/AP-1 (zeige FOSB Antikörper), and Src (zeige SRC Antikörper)/EGFR (zeige EGFR Antikörper)/JNK1 (zeige MAPK8 Antikörper)/2, Erk1/2 (zeige MAPK1/3 Antikörper)/NF-kappaB (zeige NFKB1 Antikörper) cascades.
Studies indicate the feasibility of combining two U-PA (zeige PLAU Antikörper) receptor (uPAR)-targeted probes in a preclinical head and neck cancer model.
soluble urokinase plasminogen activator receptor was associated with low left ventricular ejection fraction and elevated BNP (zeige BNC2 Antikörper).
Results suggest that soluble urokinase-type plasminogen activator receptor levels are positively correlated with severity of acute pancreatitis.
results show that the uPA (zeige PRAP1 Antikörper)/uPAR/LRP1 (zeige LRP1 Antikörper) system is a potential target for the development of therapeutic strategies to promote axonal recovery following a CNS injury
our study indicates that suPAR increases in patients with AML (zeige RUNX1 Antikörper) and this situation is associated with poorer survival. suPAR can thus be used as a diagnostic and prognostic biomarker in AML (zeige RUNX1 Antikörper) and may help in the developing of specific therapeutic targets.
Data show that urokinase-type plasminogen activator (uPA (zeige PLAU Antikörper)) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA (zeige PLAU Antikörper) receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1 (zeige SERPINE1 Antikörper)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA (zeige PLAU Antikörper)/uPAR binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
Data indicate that superoxide dismutase (SOD) inhibited high glucose (HG)-induced expression of uPAR and VEGF in bovine retinal microvascular endothelial cell (REC).
These data indicated that E. coli LPS (zeige IRF6 Antikörper) led to an increase in u-PA (zeige PLAU Antikörper) activity and RNA expression of u-PA (zeige PLAU Antikörper) and u-PAR in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
the interaction between uPAR and Man-6-P/IGF2R (zeige IGF2R Antikörper) is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/IGF2R (zeige IGF2R Antikörper) by different mechanisms.
This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.
urokinase plasminogen activator surface receptor
, plasminogen activator, urokinase receptor
, urokinase plasminogen activator receptor
, urokinase-type plasminogen activator receptor
, monocyte activation antigen Mo3
, u-plasminogen activator receptor form 2
, urokinase-type plasminogen activator (uPA) receptor
, plasminogen activator urokinase receptor 3
, urinary plasminogen activator receptor 2
, urinary plasminogen activator receptor 3